Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
The following is a summary of the Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript:
以下是Aptose Biosciences Inc.（APTO）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
In 2023, Aptose Biosciences managed to finance its activities through various sources, such as an ATM facility and a strategic investment by Hanmi Pharmaceutical.
The company closed financings with gross proceeds of $13.7 million in January.
The company ended the year with approximately $9.3 million, with a decrease in cash and investments of $27.7 million compared to December 2022.
The company recorded a net loss of about $51.2 million in 2023, translating into a $7.58 loss per share.
Having completed a financing campaign in January 2024, raising around $13.7 million, it is anticipated that the current resources will fund operations through August 2024.
Aptose raised $7.3 million through financing activities during 2023.
2023年，Aptose Biosciences设法通过各种来源为其活动提供资金，例如自动柜员机设施和韩美制药的战略投资。
该公司在1月份完成了融资，总收益为1,370万美元。
该公司在年底的收入约为930万美元，与2022年12月相比，现金和投资减少了2770万美元。
该公司在2023年录得约5,120万美元的净亏损，相当于每股亏损7.58美元。
在2024年1月完成融资活动后，筹集了约1,370万美元，预计目前的资源将为2024年8月之前的运营提供资金。
Aptose 在 2023 年通过融资活动筹集了 730 万美元。
Business Progress:
业务进展：
Aptose's lead agent Tuspetinib, demonstrated powerful anti-leukemic activity and an excellent safety profile. The company plans to prioritize resources towards the TUS/VEN/HMA triplet study for frontline treatment of newly diagnosed AML patients.
Luxeptinib, another Aptose drug has completed patient enrollment and dosing in trials for B-cell malignancy and AML. A new G3 formulation with improved absorption and beter tolerance will be used for future studies.
The company is in ongoing discussions for potential partnerships for the development of tuspetinib. The launch of TUS/VEN/HMA registrational programs is expected in 2025.
Data presentation on single agent and doublet in relapsed/refractory patients at the EHA Conference is expected in June 2024.
The company has 15,706,810 common shares outstanding and 8,332,163 warrants at the end of 2023.
Aptose的主要药物Tuspetinib表现出强大的抗白血病活性和出色的安全性。该公司计划将资源优先用于TUS/VEN/HMA三联研究，该研究旨在对新诊断的急性髓细胞白血病患者进行一线治疗。
另一种Aptose药物Luxeptinib已经完成了B细胞恶性肿瘤和急性髓细胞白血病试验的患者入组和给药。一种具有更好吸收和更好耐受性的新 G3 配方将用于未来的研究。
该公司正在讨论开发tuspetinib的潜在合作伙伴关系。TUS/VEN/HMA注册计划预计将于2025年启动。
预计将于2024年6月在EHA会议上公布有关复发/难治性患者的单一药物和双联药物的数据。
截至2023年底，该公司有15,706,810股已发行普通股和8,332,163份认股权证。
More details: Aptose Biosciences IR
更多详情： Aptose 生物科学红外线
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。